Apoptotic markers in a prostate cancer cell line: Effect of ellagic acid

Oncology Reports

Volumn 30, Issue 6, 2013, Pages 2804-2810

  Vanella, Luca ^a   Di Giacomo, Claudia ^a   Acquaviva, Rosaria ^a   Barbagallo, Ignazio ^a   Cardile, Venera ^a   Kim, Dong Hyun ^b   Abraham, Nader G ^b   Sorrenti, Valeria ^a  

^a UNIVERSITY OF CATANIA   (Italy)

^b MARSHALL UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Apoptosis; Ellagic acid; Prostate cancer

Indexed keywords

APOPTOSIS INDUCING FACTOR; APOPTOSIS REGULATORY PROTEIN; BETA CATENIN; CASPASE 3; ELLAGIC ACID; HEME OXYGENASE 1; HUMAN ANTIGEN R; INTERLEUKIN 6; MAMMALIAN TARGET OF RAPAMYCIN; P21 ACTIVATED KINASE 1; REACTIVE OXYGEN METABOLITE; SILENT INFORMATION REGULATOR 1; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL CYCLE; CONTROLLED STUDY; DOWN REGULATION; DRUG CYTOTOXICITY; ENZYME ACTIVATION; HUMAN; HUMAN CELL; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION;

APOPTOSIS; BETA CATENIN; CASPASE 3; CELL LINE, TUMOR; CELL PROLIFERATION; ELLAGIC ACID; GENE EXPRESSION REGULATION, NEOPLASTIC; HEME OXYGENASE-1; HUMANS; INTERLEUKIN-6; MALE; PROSTATIC NEOPLASMS; REACTIVE OXYGEN SPECIES;

EID: 84892426198     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2013.2757     Document Type: Article

References (67)

1. Ferlay J, Parkin DM and Steliarova-Foucher E: Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer 46: 765-781, 2010.
2. American Cancer Society: Prostate Cancer Statistics 2013. http://www.cancer.org. Accessed: May 20, 2013.
3. American Society of Clinical Oncology Prostate Cancer Statistics. http://www.cancer.net/prostate. Accessed: May 20, 2013.
4. Imamoto T, Suzuki H, Akakura K, Komiya A, Nakamachi H, Ichikawa T, Igarashi T and Ito H: Pretreatment serum level of testosterone as a prognostic factor in Japanese men with hormonally treated stage D2 prostate cancer. Endocr J 48: 573-578, 2001.
5. Chen J and Xu X: Diet, epigenetic, and cancer prevention. Adv Genet 71: 237-255, 2010.
6. Kang NJ, Shin SH, Lee HJ and Lee KW: Polyphenols as small molecular inhibitors of signaling cascades in carcinogenesis. Pharmacol Ther 130: 310-324, 2011.
7. Weng CJ and Yen GC: Chemopreventive effects of dietary phytochemicals against cancer invasion and metastasis: phenolic acids, monophenol, polyphenol, and their derivatives. Cancer Treat Rev 38: 76-87, 2012.
8. Russo A, Piovano M, Lombardo L, Vanella L, Cardile V and Garbarino J: Pannarin inhibits cell growth and induces cell death in human prostate carcinoma DU-145 cells. Anticancer Drugs 17: 1163-1169, 2006.
9. Yim D, Singh RP, Agarwal C, Lee S, Chi H and Agarwal R: A novel anticancer agent, decursin, induces G1 arrest and apoptosis in human prostate carcinoma cells. Cancer Res 65: 1035-1044, 2005.
10. Cardile V, Scifo C, Russo A, Falsaperla M, Morgia G, Motta M, Renis M, Imbriani E and Silvestre G: Involvement of HSP70 in resveratrol-induced apoptosis of human prostate cancer. Anticancer Res 23: 4921-4926, 2003.
11. Aviram M, Dornfield L, Rosenblat M, Volkova N, Kaplan M, Coleman R, Hayek T, Presser D and Fuhrman B: Pomegranate juice consumption reduces oxidative stress, atherogenic modifications to LDL, and platelet aggregation: studies in humans and in atherosclerotic apolipoprotein E-deficient mice. Am J Clin Nutr 71: 1062-1076, 2000.
12. Kaplan M, Hayek T, Raz A, Coleman R, Dornfeld L, Vaya J and Aviram M: Pomegranate juice supplementation to atherosclerotic mice reduces macrophage lipid peroxidation, cellular cholesterol accumulation and development of atherosclerosis. J Nutr 131: 2082-2089, 2001.
13. Kim ND, Mehta R, Yu W, Neeman I, Livney T, Amichay A, Poirier D, Nicholls P, Kirby A, Jiang W, Mansel R, Ramachandran C, Rabi T, Kaplan B and Lansky E: Chemopreventive and adjuvant therapeutic potential of pomegranate (Punica granatum) for human breast cancer. Breast Cancer Res Treat 71: 203-217, 2002.
14. Cerdá B, Cerón JJ, Tomás-Barberán FA and Espín JC: Repeated oral administration of high doses of pomegranate ellagitannin punicalagin to rats for 37 days is not toxic. J Agric Food Chem 51: 3493-3501, 2003.
15. Cerdá B, Llorach R, Cerón JJ, Espín JC and Tomás-Barberán FA: Evaluation of the bioavailability and metabolism in the rat of punicalagin, an antioxidant polyphenol from pomegranate juice. Eur J Nutr 42: 18-28, 2003.
16. Narayanan BA, Geoffrey O, Willingham MC, Re GG and Nixon DW: p53/p21(WAF1/CIP1) expression and its possible role in G1 arrest and apoptosis in ellagic acid-treated cancer cells. Cancer Lett 136: 215-221, 1999.
17. Khanduja KL, Gandhi RK, Pathania V and Syanl N: Prevention of N-nitrosodiethylamine-induced lung tumorigenesis by ellagic acid and quercetin in mice. Food Chem Toxicol 37: 313-318, 1999.
18. Mertens-Talcott SU, Talcott ST and Percival SS: Low concentrations of quercetin and ellagic acid synergistically influence proliferation, cytotoxicity and apoptosis in MOLT-4 human leukemia cells. J Nutr 133: 2669-2674, 2003.
19. Heber D: Multitargeted therapy of cancer by ellagitannins. Cancer Lett 269: 262-268, 2008.
20. Seeram NP, Adams LS, Henning SM, Niu Y, Zhang Y, Nair MG and Heber D: In vitro antiproliferative, apoptotic and antioxidant activities of punicalagin, ellagic acid and a total pomegranate tannin extract are enhanced in combination with other polyphenols as found in pomegranate juice. J Nutr Biochem 16: 360-367, 2005.
21. Seeram NP, Aronson WJ, Zhang Y, Henning SM, Moro A, Lee RP, Sartippour M, Harris DM, Rettig MB, Suchard MA, Pantuck AJ, Belldegrun A and Heber D: Pomegranate ellagitannin-derived metabolites inhibit prostate cancer growth and localize to the mouse prostate gland. J Agric Food Chem 55: 7732-7737, 2007.
22. Falsaperla M, Morgia G, Tartarone A, Ardito R and Romano G: Support ellagic acid therapy in patients with hormone refractory prostate cancer (HRPC) on standard chemotherapy using vinorelbine and estramustine phosphate. Eur Urol 47: 449-455, 2005.
23. Lansky EP, Harrison G, Froom P and Jiang WG: Pomegranate (Punica granatum) pure chemicals show possible synergistic inhibition of human PC-3 prostate cancer cell invasion across Matrigel. Invest New Drugs 23: 121-122, 2005.
24. Sartippour MR, Seeram NP, Rao JY, Moro A, Harris DM, Henning SM, Firouzi A, Rettig MB, Aronson WJ, Pantuck AJ and Heber D: Ellagitannin-rich pomegranate extract inhibits angiogenesis in prostate cancer in vitro and in vivo. Int J Oncol 32: 475-480, 2008.
25. Umesalma S and Sudhandiran G: Ellagic acid prevents rat colon carcinogenesis induced by 1,2 dimethyl hydrazine through inhibition of AKT-phosphoinositide-3 kinase pathway. Eur J Pharmacol 660: 249-258, 2011.
26. Vanella L, Barbagallo I, Acquaviva R, Di Giacomo C, Cardile V, Abraham NG and Sorrenti V: Ellagic acid: cytodifferentiating and antiproliferative effects in human prostatic cancer cell lines. Curr Pharm Des 19: 2728-2736, 2013.
27. Fisher ED: Apoptosis in cancer therapy: crossing the threshold. Cell 78: 539-542, 1994.
28. Hartwell HL and Kastan MB: Cell cycle control and cancer. Science 266: 1821-1828, 1994.
29. Thompson CB: Apoptosis in the pathogenesis and treatment of disease. Science 267: 1456-1462, 1995.
30. Steller H: Mechanisms and genes of cellular suicide. Science 267: 1445-1449, 1995.
31. Hunter T: Oncoprotein networks. Cell 88: 333-346, 1997.
32. Acquaviva R, Di Giacomo C, Sorrenti V, Galvano F, Santangelo R, Cardile V, Gangia S, D'Orazio N, Abraham NG and Vanella L: Antiproliferative effect of oleuropein in prostate cell lines. Int J Oncol 41: 31-38, 2012.
33. Bradford MM: A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72: 248-254, 1976.
34. Hong WK and Sporn MB: Recent advances in chemoprevention of cancer. Science 278: 1073-1077, 1997.
35. Parnes HL, Thompson IM and Ford LG: Prevention of hormone-related cancers: prostate cancer. J Clin Oncol 23: 368-377, 2005.
36. Mukhtar H and Ahmad N: Cancer chemoprevention: future holds in multiple agents. Toxicol Appl Pharmacol 158: 207-210, 1999.
37. Surh YJ: Cancer chemoprevention with dietary phytochemicals. Nat Rev Cancer 3: 768-780, 2003.
38. Greenwald P: Lifestyle and medical approaches to cancer prevention. Recent Results Cancer Res 166: 1-15, 2005.
39. Barker N and Clevers H: Catenins, Wnt signaling and cancer. Bioessays 22: 961-965, 2000.
40. Fearnhead NS, Britton MP and Bodmer WF: The ABC of APC. Hum Mol Genet 10: 721-733, 2001.
41. Karim R, Tse G, Putti T, Scolyer R and Lee S: The significance of the Wnt pathway in the pathology of human cancers. Pathology 36: 120-128, 2004.
42. Gwak J, Lee JH, Chung YH, Song GY and Oh S: Small molecule-based promotion of PKCα-mediated β-catenin degradation suppresses the proliferation of CRT-positive cancer cells. PLoS One 7: e46697, 2012.
43. Pratheeshkumar P, Budhraja A, Son YO, Wang X, Zhang Z, Ding S,Wang L, Hitron A, Lee JC, Xu M, Chen G, Luo J and Shi X: Quercetin inhibits angiogenesis mediated human prostate tumor growth by targeting VEGFR-2 regulated AKT/mTOR/P70S6K signaling pathways. PLoS One 7: e47516, 2012.
44. Kip1 modulate responsiveness of pancreatic cancer cells towards a dual PI3K/mTOR inhibitor in preclinical models. Oncotarget 4: 277-288, 2013.
45. Vinayak S and Carlson RW: mTOR inhibitors in the treatment of breast cancer. Oncology 27: 38-44, 2013.
46. Fasolo A and Sessa C: mTOR inhibitors in the treatment of cancer. Expert Opin Investig Drugs 17: 1717-1734, 2008.
47. Jo MJ, Kim HR and Kim GD: The anticancer effects of Saccharina japonica on 267B1/K-ras human prostate cancer cells. Int J Oncol 41: 1789-1797, 2012.
48. Adhami VM, Syed DN, Khan N and Mukhtar H: Dietary flavonoid fisetin: a novel dual inhibitor of PI3K/Akt and mTOR for prostate cancer management. Biochem Pharmacol 84: 1277-1281, 2012.
49. Fagone P, Donia M, Mangano K, Quattrocchi C, Mammana S, Coco M, Libra M, McCubrey JA and Nicoletti F: Comparative study of rapamycin and temsirolimus demonstrates superimposable anti-tumour potency on prostate cancer cells. Basic Clin Pharmacol Toxicol 112: 63-69, 2013.
50. Sundaresan NR, Pillai VB, Wolfgeher D, Samant S, Vasudevan P, Parekh V, Raghuraman H, Cunningham JM, Gupta M and Gupta MP: The deacetylase SIRT1 promotes membrane localization and activation of Akt and PDK1 during tumorigenesis and cardiac hypertrophy. Sci Signal 4: ra46, 2011.
51. Chen HC, Jeng YM, Yuan RH, Hsu HC and Chen YL: SIRT1 promotes tumorigenesis and resistance to chemotherapy in hepatocellular carcinoma and its expression predicts poor prognosis. Ann Surg Oncol 19: 2011-2019, 2012.
52. Jung-Hynes B, Nihal M, Zhong W and Ahmad N: Role of sirtuin histone deacetylase SIRT1 in prostate cancer. A target for prostate cancer management via its inhibition? J Biol Chem 284: 3823-3832, 2009.
53. Abdelmohsen K, Pullmann R Jr, Lal A, Kim HH, Galban S, Yang X, Blethrow JD, Walker M, Shubert J, Gillespie DA, Furneaux H and Gorospe M: Phosphorylation of HuR by Chk2 regulates SIRT1 expression. Mol Cell 25: 543-557, 2007.
54. Kuwano Y, Rabinovic A, Srikantan S, Gorospe M and Demple B: Analysis of nitric oxide-stabilized mRNAs in human fibroblasts reveals HuR-dependent heme oxygenase 1 upregulation. Mol Cell Biol 29: 2622-2635, 2009.
55. Kruger AL, Peterson S, Turkseven S, Kaminski PM, Zhang FF, Quan S, Wolin MS and Abraham NG: D-4F induces heme oxygenase-1 and extracellular superoxide dismutase, decreases endothelial cell sloughing, and improves vascular reactivity in rat model of diabetes. Circulation 111: 3126-3134, 2005.
56. Miramar MD, Costantini P, Ravagnan L, Saraiva LM, Haouzi D, Brothers G, Penninger JM, Peleato ML, Kroemer G and Susin SA: NADH oxidase activity of mitochondrial apoptosis-inducing factor. J Biol Chem 276: 16391-16398, 2001.
57. Klein JA, Longo-Guess CM, Rossmann MP, Seburn KL, Hurd RE, Frankel WN, Bronson RT and Ackerman SL: The harlequin mouse mutation downregulates apoptosis-inducing factor. Nature 419: 367-374, 2002.
58. Otera H, Ohsakaya S, Nagaura Z, Ishihara N and Mihara K: Export of mitochondrial AIF in response to proapoptotic stimuli depends on processing at the intermembrane space. EMBO J 24: 1375-1386, 2005.
59. Susin SA, Lorenzo HK, Zamzami N, Marzo I, Snow BE, Brothers GM, Mangion J, Jacotot E, Costantini P, Loeffler M, Larochette N, Goodlett DR, Aebersold R, Siderovski DP, Penninger JM and Kroemer G: Molecular characterization of mitochondrial apoptosis-inducing factor. Nature 397: 441-446, 1999.
60. Cregan SP, Fortin A, MacLaurin JG, Callaghan SM, Cecconi F, Yu SW, Dawson TM, Dawson VL Park DS Kroemer G and Slack RS: Apoptosis-inducing factor is involved in the regulation of caspase-independent neuronal cell death. J Cell Biol 158: 507-517, 2002.
61. Ling YH, Liebes L, Zou Y and Perez-Soler R: Reactive oxygen species generation and mitochondrial dysfunction in the apoptotic response to Bortezomib, a novel proteasome inhibitor, in human H460 non-small cell lung cancer cells. J Biol Chem 278: 33714-33723, 2003.
62. Paradies G, Petrosillo G, Pistolese M and Ruggiero FM: Reactive oxygen species affect mitochondrial electron transport complex I activity through oxidative cardiolipin damage. Gene 286: 135-141, 2002.
63. Malik A, Afaq S, Shahid M, Akhtar K and Assiri A: Influence of ellagic acid on prostate cancer cell proliferation: a caspase-dependent pathway. Asian Pac J Trop Med 4: 550-555, 2011.
64. Smith PC, Hobisch A, Lin DL, Culig Z and Keller ET: Interleukin-6 and prostate cancer progression. Cytokine Growth Factor Rev 12: 33-40, 2001.
65. Cavarretta IT, Neuwirt H, Untergasser G, Moser PL, Zaki MH, Steiner H, Rumpold H, Fuchs D, Hobisch A, Nemeth JA and Culig Z: The antiapoptotic effect of IL-6 autocrine loop in a cellular model of advanced prostate cancer is mediated by Mcl-1. Oncogene 26: 2822-2832, 2007.
66. Culig Z and Puhr M: Interleukin-6: a multifunctional targetable cytokine in human prostate cancer Mol Cell Endocrinol 360: 52-58, 2012.
67. Yang F, Strand DW and Rowley DR: Fibroblast growth factor-2 mediates transforming growth factor-β action in prostate cancer reactive stroma. Oncogene 27: 450-459, 2008.